Regencell Bioscience (NASDAQ:RGC) Shares Climb 7% – What’s Next?

Posted by Brenda Bartman on Oct 6th, 2026

Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) shares traded up 7% on Tuesday. The stock traded as high as $7.90 and last traded at $7.75. Approximately 186,897 shares changed hands during mid-day trading, a decline of 34% from the average daily volume of 284,048 shares. The stock had previously closed at $7.24.

Analyst Ratings Changes

A number of research firms recently commented on RGC. Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, September 21st. Wall Street Zen downgraded Regencell Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Read Our Latest Stock Analysis on Regencell Bioscience

Regencell Bioscience Price Performance

The firm’s 50-day moving average is $5.86 and its 200-day moving average is $15.21.

Hedge Funds Weigh In On Regencell Bioscience

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE increased its holdings in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares during the period. Amundi bought a new stake in Regencell Bioscience during the 1st quarter valued at approximately $219,000. Finally, Seven Fleet Capital Management LP purchased a new stake in Regencell Bioscience in the fourth quarter worth about $92,000. 0.13% of the stock is owned by institutional investors.

Regencell Bioscience Company Profile

(Get Free Report)

Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges.

The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions.